Abatacept Reduces Levels of Switched Memory B Cells, Autoantibodies, and Immunoglobulins in Patients with Rheumatoid Arthritis
Authors:
- Lucia PaoliniLPLucia Paolini
- Doris RicottaDRDoris Ricotta
- Antonio PedriniAPAntonio Pedrini
- Silvia PiantoniSilvia Piantoni
- Luigi CaimiLCLuigi Caimi
- Angela TincaniATAngela Tincani
- Paolo AiròPAPaolo Airò
- 1 March 2014
- journal article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 41 (4) , 666-672
Abstract
Objective.: Abatacept (ABA) is a chimeric molecule, able to block the CD28-mediated costimulatory pathway. To evaluate the hypothesis that, through this mechanism of action, ABA may down-modulate the immune responses of B lymphocytes in rheumatoid arthritis (RA), we investigated the serum levels of immunoglobulins (Ig), free light chains (FLC), anticitrullinated protein antibodies (ACPA), and rheumatoid factor (RF), as well as the number of B lymphocytes differentiated into post-switch memory cells in patients treated with ABA.Methods.: The serum levels of Ig, FLC, different ACPA, RF isotypes, and the B cell phenotype were longitudinally evaluated in 30 patients with RA treated with ABA.Results.: At baseline, the proportion of total and post-switch memory B cells was lower in RA than in healthy individuals. After 6 months of ABA treatment we observed significant reductions of serum levels of IgG, IgA, and IgM, as well as FLC, with a normalization in many patients who had initially abnormal values. A significant reduction of the titers of IgG- and IgA-ACPA, as well as of IgM-, IgA-, and IgG-RF was also observed. A decrease of autoantibodies below the upper limits of normal values was found in 2 of 26 patients (8%) initially seropositive for IgG-ACPA, 1 of 14 (7%) for IgA-ACPA, 5 of 22 (23%) for IgM-RF, 7 of 22 (30%) for IgA-RF, and 5 of 16 (31%) for IgG-RF. After treatment, the proportion of circulating post-switch memory B cells was also further significantly decreased.Conclusion.: ABA treatment in patients with RA can reduce signs of polyclonal B cell activation, inducing a trend toward normalization of serum levels of different classes of Ig and of FLC, decreasing titers of ACPA and RF, and percentages of post-switch memory B cells.Keywords
This publication has 36 references indexed in Scilit:
- Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registryAnnals of the Rheumatic Diseases, 2012
- Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activityAnnals of the Rheumatic Diseases, 2010
- Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohortArthritis Research & Therapy, 2009
- Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot studyAnnals of the Rheumatic Diseases, 2009
- Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factorArthritis Research & Therapy, 2009
- Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rateAnnals of the Rheumatic Diseases, 2009
- Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritisArthritis Research & Therapy, 2009
- Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of responseAnnals of the Rheumatic Diseases, 2008
- High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor α inhibitors in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2007
- Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjögren's syndromeAnnals of the Rheumatic Diseases, 2007